Innsbruck

• A pivotal study of N-Acetyl-L-Leucine on CACNA1A Disorders Pending
  2025-523828-51-00 5 CACNA1A Disorders
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• Darovasertib before Surgery or Radiation Therapy to Treat Early-stage Eye Cancer (Uveal Melanoma) Recruiting
  2025-522387-32-00 5 2026-04-10 Uveal Melanoma
• A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) Recruiting
  2025-521792-31-01 5 2026-04-07 Homozygous Familial Hypercholesterolemia (HoFH)
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma Recruiting
  2025-521785-10-00 5 2026-03-04 Glioblastoma
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting
  2025-521276-59-00 5 2025-12-16 Autosomal dominant polycystic kidney disease (ADPKD)
• SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION Recruiting
  2025-520794-39-00 5 2025-12-10 Arterial Hypertension
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm … Recruiting
  2025-521268-37-00 6 2025-11-25 Respiratory tract diseases
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri … Recruiting
  2024-516525-31-01 5 2025-07-14 Primary Biliary Cholangitis

Showing 25–48 of 347 trials